The study also reported small, asymptomatic increases in amylase levels in the semaglutide group, without cases of pancreatitis
Whether due to lack of coverage, plan exclusions, prior authorisation denials, or income thresholds that disqualify assistance programs
In August 2025 , the FDA approved Wegovy for another use: to treat a type of fatty liver disease called metabolic dysfunction-associated steatohepatitis (MASH) in adults who have moderate to advanced liver scarring (fibrosis) but do not have permanent liver damage (cirrhosis)
It can be stopped abruptly without causing withdrawal or harm
CVOT=cardiovascular outcomes trial
Anatomical, physiological, and functional diversity of adipose tissue